Gastrointestinal Physiology Laboratory, CIBERehd CSdM-UAB, Hospital de Mataró, 08404 Mataró, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Hepato-Digestivas (CIBERehd) Instituto de Salud Carlos III, 28029 Madrid, Spain.
Nutrients. 2020 Jun 23;12(6):1873. doi: 10.3390/nu12061873.
Thickened fluids are a therapeutic strategy for oropharyngeal dysphagia (OD). However, its therapeutic effect among different phenotypes of OD patients has not yet been compared. We aimed to assess the therapeutic effect and α-amylase resistance of a mixed gum/starch thickener [Fresubin Clear Thickener (FCT)] on four phenotypes of OD patients: G1) 36 older; G2) 31 head/neck cancer (HNC); G3) 30 Parkinson's disease; and G4) 31 chronic post-stroke. Therapeutic effect of FCT was assessed during videofluoroscopy using the Penetration-Aspiration Scale (PAS), for 5/20 mL boluses, at four levels of shear-viscosity (<50, 250, 1000 and 2000 mPa·s). The effect of α-amylase was assessed after 30 s of oral incubation. Patients had high prevalence of VFS signs of impaired efficacy (98.44%) and safety (70.31%) of swallow with a severe PAS score (4.44 ± 0.20). Most severe OD was in HNC (80.6% unsafe swallows). FCT showed a strong therapeutic effect on the safety of swallow at a range between 250-1000 mPa·s (74.19-96.67%, safe swallows in G1, G3, G4, and 58.06% in G2), without increasing pharyngeal residue. Viscosity was unaffected by α-amylase. Increasing shear-viscosity with FCT causes a strong viscosity-dependent therapeutic effect on the safety of swallow. This effect depends on the phenotype and is similar among older, Parkinson's and post-stroke patients.
浓稠的液体是治疗口咽吞咽困难(OD)的一种策略。然而,其在不同类型 OD 患者中的治疗效果尚未进行比较。我们旨在评估混合胶/淀粉增稠剂[Fresubin Clear Thickener(FCT)]对 4 种 OD 患者表型的治疗效果和α-淀粉酶抗性:G1)36 例老年人;G2)31 例头颈部癌症(HNC);G3)30 例帕金森病;和 G4)31 例慢性脑卒中。使用透视吞咽功能检查(VFS)通过渗透-吸入量表(PAS)评估 FCT 的治疗效果,用于 5/20 mL 推注,在 4 个剪切粘度水平(<50、250、1000 和 2000 mPa·s)下进行。在口腔孵育 30 秒后评估α-淀粉酶的作用。患者吞咽的 VFS 有效性(98.44%)和安全性(70.31%)均有较高的迹象,吞咽的 PAS 评分严重(4.44±0.20)。最严重的 OD 发生在 HNC(80.6%的不安全吞咽)。FCT 在 250-1000 mPa·s 之间的范围对吞咽的安全性具有很强的治疗效果(74.19-96.67%,G1、G3、G4 和 G2 中的安全吞咽),而不会增加咽部残留物。粘度不受α-淀粉酶的影响。FCT 增加剪切粘度会对口咽吞咽的安全性产生强烈的依赖于粘度的治疗效果。这种效果取决于表型,并且在老年人、帕金森病和脑卒中后患者中相似。